ITRMFPNKHealthcare

Iterum Therapeutics plc

Reports in 2d· 2026-04-29

-96.9% · 90d

$0.01

-0.01 (-47.12%)

News

No News Yet

Press releases and SEC filings for ITRMF will appear here as they are published.

Check back later for updates

Key Data

Market Cap$538,244

Open$0.01

Prev Close$0.02

Day Range$0.01 – $0.02

52W Range$0.01 – $1.34

Volume41,850

P/E (TTM)—

EPS$-0.72

Dividend Yield—

Beta3.36

Next Earnings2026-04-29(2d)

Analyst Ratings

Hold1 analysts

Buy 0Hold 1Sell 0

About

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.

Healthcare · Biotechnology

9 employees

www.iterumtx.com

Top Institutional Holders

As of 2025-12-31

Byrne Asset Management LLC$1

3 sh● NEW

See all holders →

Quarterly Financials

09/25

Revenue Net Income